Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics, Inc., headquartered in New Haven, Connecticut, has recently developed Haduvio (oral nalbuphine ER) as a potential treatment for chronic cough in IPF and refractory chronic cough.

Virtual Meeting to be held on April 28-30 hosted by B. Riley.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary ...

Meeting to be held in London, England on April 15 and in Zurich, Switzerland on April 16 hosted by Cantor Fitzgerald. Discover outperforming stocks and invest smarter with Top Smart Score Stocks ...